AIDX.TO stock opens pre-market at C$0.69 on 02 Mar 2026, with volume running above the average at 1,415,147 shares. Investors will watch Healwell AI Inc. (AIDX.TO, TSX) as management presents at multiple March conferences. The company sits in the Healthcare sector and shows mixed fundamentals: a C$208,798,326.00 market cap, EPS -0.26, and PE -2.88. Conference visibility and short-term momentum may determine near-term trading ranges for this AI-focused healthcare name.

Quick snapshot of AIDX.TO stock and market position

Healwell AI Inc. (AIDX.TO, TSX) trades at C$0.69 with a day range of C$0.64–C$0.72 and a 52-week range of C$0.58–C$1.81. Market cap stands at C$208,798,326.00 and shares outstanding are 278,397,768.00. Average daily volume is 511,501.00; today’s volume is 1,415,147.00, or a relative volume of 3.26. The company focuses on AI-enabled preventative care and has an alliance with WELL Health Technologies to scale clinical decision support tools.

Catalysts and AIDX.TO stock conference schedule

Healwell executives will present at three investor conferences in March 2026. Presentations include TD Cowen on March 3, Scotiabank TMT on March 4, and the ROTH conference March 23. These events create opportunities for fresh institutional interest and one-on-one meetings. Management commentary and slide detail could move short interest and liquidity. See the company release for details: Newsfile release and Nasdaq press release.

Fundamentals, valuation and Meyka AI grade for AIDX.TO stock

Healwell shows mixed fundamentals. Trailing metrics include EPS -0.26 and PE -2.88. Key ratios: price-to-sales 2.08, price-to-book 1.48, current ratio 0.85, and debt-to-equity 0.74. Cash per share is 0.07 and book value per share is 0.52. Sales per share are 0.42, and operating cash flow per share is -0.10.

Meyka AI rates AIDX.TO with a score out of 100: 53.89 / C+ — HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Technicals and trading signals for AIDX.TO stock

Momentum indicators show mixed signals. RSI sits at 45.90, near neutral. MACD is slightly negative (MACD -0.05, signal -0.06). ADX at 39.63 signals a strong trend environment but direction is mixed. Bollinger Bands middle is C$0.69 with upper C$0.84 and lower C$0.55. Short-term traders may watch the 50-day average C$0.80 and the 200-day average C$1.19 as resistance levels.

Risks and opportunities tied to AIDX.TO stock

Risks: the company reports negative profitability and negative operating cash flow per share, with net margins at -59.11% and a current ratio under 1.00. Low liquidity at higher price points and limited analyst coverage raise execution risk. Opportunities: conference exposure could attract institutional buyers and strategic partnerships may expand commercial adoption of its AI platform. The Healthcare sector’s uneven YTD performance may pressure multiples but also rewards validated clinical outcomes.

Valuation outlook and AIDX.TO stock forecast

Meyka AI’s forecast model projects short-term targets of C$0.56 (quarterly) and a yearly projection of C$0.43. The model-based near-term target of C$0.56 implies a -18.84% move versus the current C$0.69, while the yearly projection of C$0.43 implies -37.68%. There is upside case work if Healwell secures commercial contracts or posts improved margins; a recovery price target of C$1.20 would require material revenue and margin gains. Forecasts are model-based projections and not guarantees. For more trading context see the Meyka stock page: https://meyka.ai/stocks/AIDX.TO.

Final Thoughts

AIDX.TO stock trades pre-market at C$0.69 on 02 Mar 2026 with active volume and a clear event calendar. Fundamentals show negative EPS (-0.26) and constrained liquidity metrics, while valuation compares unfavourably to broader Healthcare peers by margins and cash flow. Meyka AI’s forecast model projects a quarterly estimate of C$0.56 and a yearly projection of C$0.43, implying downside of -18.84% and -37.68% respectively versus the current price. Conference participation this month is the key short-term catalyst. If Healwell converts investor interest into contracts and margin expansion, a recovery toward C$1.20 becomes plausible, but that requires measurable top-line and operating improvements. Investors should weigh elevated volatility and execution risk against the company’s AI-driven preventative care exposure. Meyka AI, an AI-powered market analysis platform, flags this name as a HOLD per current data and advises monitoring earnings on 2026-03-26 and conference updates closely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.